Medigen bet it all on a vaccine approved on Phase 2 data — the export door never opened

Medigen Vaccine Biologics was a small Taiwanese biotech whose future came to rest on one product: MVC-COV1901, a COVID-19 vaccine developed with the US National Institutes of Health. On July 19, 2021, Taiwan granted it an emergency use authorization based on Phase 2 data alone. The health ministry said the vaccine produced neutralizing antibodies 'no worse than' AstraZeneca's, but there was no efficacy data from a large trial — the authorization rested on antibody levels, not on proof the vaccine prevented disease.

The state had already committed — the government contracted with Medigen for five million doses, with an agreement for five million more. Yet the market was unimpressed: the shares closed down 1.35% on the day of the announcement, against a 0.6% market fall. The approval soon became a scandal. The wife of a member of the vaccine review panel had bought 20,000 shares at about NT$260.5 on the morning of the announcement and sold them a few days later at about NT$268, a profit of NT$151,000; she was indicted for insider trading and her husband, the panel member, for leaking the decision.

The recognition the business case needed never arrived. In August 2023 the WHO added Medigen's technology to its C-TAP pool through an out-licensing agreement with the Medicines Patent Pool — a technology-sharing arrangement, not an emergency-use listing of the vaccine itself. By then the emergency was over and the company had nothing else of scale. In fiscal 2025 it lost NT$281.71 million on revenue of NT$613.17 million, and in July 2026 its shares traded at about NT$51.

Bet everything on a single vaccine approved without efficacy data; when COVID demand vanished, no second product, and FY2025 still lost NT$281.71M.

Authorized on antibody data, not efficacy: the EUA rested on Phase 2 results — no efficacy proof from a large trial — so no foreign regulator or WHO listing followed, and the export door stayed shut.

Single-product bet: everything rode on MVC-COV1901; when COVID demand disappeared there was no second engine — fiscal 2025 still showed a NT$281.71M net loss on NT$613.17M of revenue.

Governance overhang: a review-panel member's wife traded on the morning of the EUA announcement and was indicted for insider trading — the scandal kept the vaccine under a cloud for years.

The market never believed the story: the stock closed down on the day of the approval — investors had priced in the EUA long before it arrived.

An emergency authorization is not a market. Medigen's EUA rested on antibody data, not efficacy — no foreign regulator followed, and five years later it was loss-making with nothing else to sell.